为解决阿尔茨海默病（AD）中 Aβ 42 毒性问题，研究人员开展了 hiPSC-NSC-EVs 对 Aβ 42 寡聚体（Aβ 42 o）诱导人神经元损伤影响的研究。结果发现 hiPSC-NSC-EVs 能显著减轻神经元损伤，这为 AD 治疗提供了新方向。

据中国贸易救济信息网消息，2025年4月16日，应美国企业Arkema, Inc.于2025年3月27日的申请，美国商务部宣布对进口自中国台湾地区的单体和低聚物(Certain Monomers and Oligomers)发起反倾销和反补贴调查、对进口自韩国的单体和低聚物发起反倾销调查。

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

While misfolded SOD1 proteins (among others) cause ALS, misfolded amyloid beta oligomers cause Alzheimer's disease. "These are good proteins gone bad," Klein said. "They are good proteins, but when ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease affecting the frontal and temporal lobes that ...

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is an attractive therapeutic target due to its involvement in cancer and neurodegenerative diseases. Researchers from the ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...

The company reported positive results from the INTERCEPT-AD Phase I study, showing that sabirnetug was well tolerated and demonstrated novel target engagement of A-beta oligomers. Acumen ...